6 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... 40, F:M 9:1 • Clinical ... Manifestations: Malar rash ... Positive in 60-80% of cases ... #Summary #rheumatology
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
Suspect: Clinical ... Non-autoimmune rheumatologic ... NPSLE): • May involve ... Chronic B-cell activation ... #Diagnosis #Rheumatology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Macrophage Activation ... erythematosus ... Petechial or purpuric rash ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... Discontinuation of causal ... Erythematosus ( ... comparison #table #rheumatology
Scleroderma Renal Crisis (SRC)

Clinical Presentation of Scleroderma Renal Crisis:
1) Acute kidney injury
2) Abrupt onset of hypertension
3)
Crisis (SRC) Clinical ... is unknown but may ... endothelial cell activation ... , add other BP meds ... Renal #Crisis #rheumatology
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
rash on the face ... auricular papules Clinical ... cause weakness ... Dermatomyositis #diagnosis #management ... #rheumatology #